Bennett, Mark F. http://orcid.org/0000-0002-3561-6804
Oliver, Karen L.
Regan, Brigid M.
Bellows, Susannah T.
Schneider, Amy L. http://orcid.org/0000-0001-5260-7187
Rafehi, Haloom
Sikta, Neblina
Crompton, Douglas E. http://orcid.org/0000-0002-0776-1203
Coleman, Matthew http://orcid.org/0000-0001-8627-3322
Hildebrand, Michael S.
Corbett, Mark A. http://orcid.org/0000-0001-9298-3072
Kroes, Thessa
Gecz, Jozef http://orcid.org/0000-0002-7884-6861
Scheffer, Ingrid E.
Berkovic, Samuel F. http://orcid.org/0000-0003-4580-841X
Bahlo, Melanie http://orcid.org/0000-0001-5132-0774
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (GNT1102971, 1155224, 1091593, 1091593)
Cerebral Palsy Alliance Research Foundation
Manatu Hauora | Health Research Council of New Zealand
Article History
Received: 29 August 2019
Revised: 5 February 2020
Accepted: 3 March 2020
First Online: 16 March 2020
Compliance with ethical standards
:
: IES has served on scientific advisory boards for UCB, Eisai, GlaxoSmithKline, BioMarin, Nutricia and Xenon Pharmaceuticals; editorial boards of the <i>Annals of Neurology, Neurology</i> and <i>Epileptic Disorders</i>; may accrue future revenue on pending patent WO61/010176 (filed: 2008): Therapeutic Compound; has received speaker honoraria from GlaxoSmithKline, Athena Diagnostics, UCB, BioMarin, Eisai and Transgenomics; has received funding for travel from Athena Diagnostics, UCB, Biocodex, GlaxoSmithKline, Biomarin and Eisai. The remaining authors declare no competing interests.